MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

23-Nov-2010 - USA

MDxHealth SA announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences for diagnostic applications in bladder cancer.

Under the agreement, MDxHealth grants Predictive Biosciences exclusive rights for the use of a number of its DNA methylation biomarkers in bladder cancer testing in the United States. MDxHealth retains exclusive worldwide rights to these markers in tissue-based bladder cancer tests. In return, MDxHealth will receive upfront and milestone payments and royalties on net sales. Predictive Biosciences is one of the few diagnostic companies with a strong focus on applications in urologic oncology, including bladder cancer.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy